Anticoagulants to prevent placenta-mediated pregnancy complications: a review of current evidence

Dao, Vi; Rodger, Marc

doi:10.1097/moh.0b013e32832ea307

Cited by 13 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…326 We consider these fi ndings more credible than those of the two lower-quality randomized was stopped before reaching its planned sample size of 276 when an interim analysis performed because of slow accrual suggested a statistically signifi cant decrease in the primary outcome, potentially exaggerating the treatment effect. 322,323 Recommendation 11.1.1. For women considered at risk for preeclampsia, we recommend low-dose aspirin throughout pregnancy, starting from the second trimester, over no treatment (Grade 1B) .…”

Section: Lmwh and Aspirin Vs No Treatment Or Placebomentioning

confidence: 99%

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Bates

Greer

Middeldorp

et al. 2012

Chest

1,287

591

View full text Add to dashboard Cite

Summary of RecommendationsNote on Shaded Text: Throughout this guideline, shading is used within the summary of recommendations sections to indicate recommendations that are newly added or have been changed since the publication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Recommendations that remain unchanged are not shaded. Abbreviations: APLA 5 antiphospholipid antibody; aPPT 5 activated partial thromboplastin time; HIT 5 heparin-induced thrombocytopenia; INR 5 international normalized ratio; LMWH 5 low-molecular-weight heparin; NNT 5 number needed to treat; PE 5 pulmonary embolism; RR 5 risk ratio; UFH 5 unfractionated heparin

show abstract

Section: Lmwh and Aspirin Vs No Treatment Or Placebomentioning

confidence: 99%

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Bates

Greer

Middeldorp

et al. 2012

Chest

1,287

591

View full text Add to dashboard Cite

show abstract

“…11 Thus, the potential benefits of heparin administration need to be examined in adequately powered and methodologically sound randomized clinical trials. 12 With this as background, we designed the Heparin in pregnant women with Adverse Pregnancy outcome to improve the rate of successful PregnancY (HAPPY) trial, a fully academic, independent, multicenter, prospective, controlled, open-label study aimed to compare event recurrence in women considered at increased risk because of previous late pregnancy complications, who were randomly allocated to treatment with a low-molecularweight heparin in addition to medical surveillance or to medical surveillance alone.…”

Section: Introductionmentioning

confidence: 99%

Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial

Martinelli

Ruggenenti

Cetin

et al. 2012

Blood

116

102

View full text Add to dashboard Cite

To assess whether antithrombotic prophylaxis with low-molecular-weight heparin effectively prevents recurrence of late pregnancy complications, 135 women with previous history of preeclampsia, hemolytic anemia, elevated liver enzymes and low platelet count syndrome, intrauterine fetal death, fetal growth restriction, or placental abruption who had been referred within the 12th gestational week were randomized to medical surveillance alone (n ‫؍‬ 68

show abstract

“…For the most part, poor obstetric outcomes result from hemostatic disturbances, which cause obstruction in the placental vessels [14]. In recent studies, placenta-associated complications (IUFD, IUGR, RPL, pre-eclampsia, and placental abruption) have been confirmed as the leading causes of maternal/fetal morbidity and mortality [15,16].…”

Section: Discussionmentioning

confidence: 99%

Does anticoagulant therapy improve adverse pregnancy outcomes in patients with history of recurrent pregnancy loss?

Aynıoğlu

Işık²,

Şahbaz³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Objectives: Recurrent pregnancy loss (RPL) is a serious problem in the reproductive age women. We aimed to study the role of anticoagulant therapy on pregnancy complications and perinatal outcomes in pregnant patients with histories of RPL. Material and methods:One hundred fifty-three pregnants, with RPL history and thrombophilia positivity, were grouped into two as 89 treated with anticoagulant therapy and 64 non-treated. Treated and untreated groups were compared for pregnancy complications, delivery weeks, abortion rates, fetal birth weights, APGAR scores, live birth rates, and newborn intensive care admission rates.Results: Of the total 153 pregnant patients (63%) 97 developed pregnancy complications; 55 (56.7%) were in the untreated group and 42 (43.3%) were in the treated group, which was statistically significant (p = 0.003). The differences in pregnancy complications were produced by differences in the numbers of IUFDs and anembryonic fetuses among the groups. The average neonatal birth weights of infants whose mothers had taken LMWH + ASA were significantly higher (p=0.011). The prematurely delivered infants were admitted to the neonatal intensive care unit (NICU), and the NICU requirements were not statistically different between the groups (p = 0.446). However, live birth rates were significantly higher in the treated group than in the untreated group (p = 0.001).Conclusions: Anticoagulant therapy improves pregnancy complications and live birth rates in patients with RPL and hereditary thrombophilia.

show abstract

Anticoagulants to prevent placenta-mediated pregnancy complications: a review of current evidence

Cited by 13 publications

References 40 publications

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

VTE, Thrombophilia, Antithrombotic Therapy, and Pregnancy

Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial

Does anticoagulant therapy improve adverse pregnancy outcomes in patients with history of recurrent pregnancy loss?

Contact Info

Product

Resources

About